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ABSTRACT 
A contributing factor in the rising costs of the Military Healthcare System (MHS) 
budget is the pharmacy benefit.  In efforts to reduce or contain the costs associated with 
this benefit, the MHS has implemented several cost saving strategies that were adopted 
directly from private health care organizations. These strategies include formulary 
restrictions, generic substitutions, and beneficiary cost sharing that uses a tiered co-
payment structure. These strategies are primarily designed to save costs by influencing 
the behaviors and attitudes of beneficiaries, restricting their access to options with higher 
costs, and directly shifting a portion of the programs cost through co-payments. This 
thesis concludes that by implementing these utilization management strategies, the MHS 
has experienced results that are as good as or better than those experienced by the civilian 
sector.  However, Tricare pharmacy expenditures continue to increase at a faster rate than 
other components of the MHS demonstrating that the implementation of these strategies, 
though successful when compared to civilian benchmarks, have not sufficiently contained 
Tricare pharmacy expenditures. To be successful, the DoD must use a multifaceted 
approach to contain these escalating expenditures.  Ultimately, dramatic cost shifting may 
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EXECUTIVE SUMMARY 
Over the past six years, the budget for the Military Healthcare System (MHS), 
also known as Tricare, has doubled in size. It rose from $19 billon in the year 2001 to 
approximately $38 billion in 2006 (Evaluation of the Tricare Program, 2006).  A 
contributing factor to these rising expenditures is the pharmacy benefit which is the 
single largest component of the military health system’s budget.  In 2005, the pharmacy 
benefit accounted for 15 percent of the total MHS’ budget.  Its escalating costs include 
the steady increases in utilization and cost of the prescription drug benefit of the MHS 
population. Spending on the outpatient pharmacy program alone increased from $3 
billion in 2001 to over $5.4 billion in 2005 (Evaluation of the Tricare Program, 2006). 
Although the MHS has implemented several initiatives to manage the cost of the 
pharmacy benefit many of these cost saving strategies were adopted directly from private 
health care organizations and may not consider the unique mission of the MHS. These 
strategies include formulary restrictions, generic substitutions, and beneficiary cost 
sharing that uses a tiered co-payment structure. They are primarily designed to save costs 
by influencing the behaviors and attitudes of beneficiaries, restricting their access to 
options with higher costs, and directly shifting a portion of the programs cost through co-
payments. To determine the effectiveness of these strategies when applied to the military 
pharmaceutical benefit program it is paramount to understand the Military Health Care 
System and the population it serves and the unique benefits provided to the Armed Forces 
by the United States government and the challenges to meet them. Additionally, it is 
important to evaluate current trends in the pharmacy industry and compare them to those 
occurring in the MHS. 
 Over the past 10 years, the MHS began implementing civilian sector 
utilization management strategies designed to slow increases in pharmacy expenditures.  
The MHS has experienced results that are as good as or better than those experienced by 
the civilian sector.  If matching the results achieved in the civilian sector is the 
benchmark for success, then implementing civilian sector utilization management 
strategies has been successful.      
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  However, the Tricare Pharmacy program is projected to continue to increase at a 
faster rate than other components of the MHS.  Consequently, this continual increase in 
the pharmacy budget in proportion to the overall MHS budget demonstrates that the 
implementation of these civilian utilization management practices, though successful 
when compared to civilian benchmarks, have not sufficiently contained Tricare pharmacy 
expenditures. 
In response to escalating costs, the civilian sector is continually shifting a greater 
portion of the cost burden to their beneficiaries through higher co-payments and larger 
insurance premiums or simply reducing the benefits they offer.  History shows that 
Congress’s response to escalating Tricare expenditures has been to implement civilian 
strategies to increase efficiency and cost effectiveness but simultaneously they increase 
benefits and reduce out of pocket expenses for beneficiaries.  As pressure to contain 
expenditures continues to mount, Congress may be swayed to change its past behavior 
and follow the civilian sector by shifting a portion of the cost burden to beneficiaries. 
The current Tricare pharmacy benefit uses a three tiered co-payment schedule that 
requires a beneficiary to pay very modest co-payments when compared to the civilian 
sector.  These co-payments are in no way representative of the true cost of the benefit and 
some may argue that in relative terms the difference between the co-payment, $3 for 
generic and $9 for formulary, are so small compared to the actual cost that they do not 
provide incentive for beneficiaries to differentiate between them. 
Tricare beneficiaries have lower per beneficiary prescription drug utilization and 
expenditures rates than the civilian population.  The utilization of generic drugs by 
Tricare beneficiaries has increased every year since the introduction of the three tiered 
co-payment schedule and today over 53 percent of all prescriptions filled in the MHS are 
generic.   This is similar to the generic utilization rates in the civilian health care industry.  
This would seem to indicate that the current co-payments schedule does differentiate 
between drug tiers and provides as much incentive and behavior modification as the 
much higher rates charged in the civilian sector.  Proportionally raising each of the 
current co-payments in the schedule would not provide Tricare beneficiaries more 
incentive to change behaviors; it would just be a cost shifting mechanism.   
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In the Military Health System the place where an MHS beneficiary fills their 
prescription directly affects expenditures.  Expenditures for prescription drugs obtained 
from Tricare retail pharmacies (TRRx) are typically much higher than those dispensed 
through Military Treatment Facility (MTF) pharmacies or the Tricare Mail Order 
Pharmacy (TMOP).  This is primarily due to volume purchase price negotiations and the 
interpretation of the Veterans Health Care Act of 1992.  Drugs dispensed at MTF 
pharmacies and the TMOP are purchased at prices negotiated by the Defense Supply 
Center in Philadelphia and the Department of Veterans Affairs directly with drug 
manufacturers.  These negotiated prices do not apply to retail pharmacies and as such the 
prices at retail pharmacies can be two and even three times as much.  The current tiered 
co-payment schedule does not differentiate between these points of services. 
Defense Department officials proposed to change the pharmacy co-payment 
schedule in the FY 2007 budget request.  The new co-payment schedule appears to be 
designed to provide incentives for beneficiaries to make cost effective choices when 
choosing a point of service to fill prescriptions.  Based on the research in this thesis, 
incentivising beneficiaries to avoid the TRRx is an effective cost strategy.  Time will 
show if the new co-payments are large enough to actually influence the desired 
beneficiary behavior.       
The reason that the TRRx is the most expensive point of service to use is that 
DoD is unable to apply federal pricing at the TRRx, while it is able to do so at the MTF 
and TMOP.  DoD would like to apply federal pricing at the TRRx and have made 
attempts to do so.  Drug manufactures are apposed to this and argue that there is no legal 
basis under the Veterans Health Care Act of 1992 for DoD to be allowed to apply these 
discounts at the TRRx.  This issue is currently being debated by the U.S. Court of 
Appeals for the Federal Circuit.    
Ultimately DoD must use a multifaceted approach to contain the escalating 
expenditures of the pharmacy program.  Incentivising beneficiaries to choose high value 
drugs dispensed through the least expensive point of service will dramatically impact the 
current expenditures.  If the DoD is unable to secure federal pricing at the TRRx they 
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must ensure that beneficiaries have the appropriate incentives to migrate to the TMOP.  If 
not, dramatic cost shifting may be the only way to lower expenditures 
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I. RISING COSTS IN THE MHS PHARMACY BENEFIT 
Over the past six years, the budget for the Military Healthcare System (MHS), 
also known as Tricare, has doubled in size. It rose from $19 billon in the year 2001 to 
approximately $38 billion in 2006 (Evaluation of the Tricare Program, 2006).  A 
contributing factor to these rising expenditures is the pharmacy benefit which is the 
single largest component of the MHS’ budget.  In 2005, the pharmacy benefit accounted 
for 15 percent of the total military health system’s budget.  Its escalating costs include the 
steady increases in utilization and cost of the prescription drug benefit of the MHS 
population. Spending on the outpatient pharmacy program alone increased from $3 
billion in 2001 to over $5.4 billion in 2005 (Evaluation of the Tricare Program, 2006). 
Although the MHS has implemented several initiatives to manage the cost of the 
pharmacy benefit many of these cost saving strategies were adopted directly from private 
health care organizations and may not consider the unique mission of the MHS. These 
strategies include formulary restrictions, generic substitutions, and beneficiary cost 
sharing that uses a tiered co-payment structure. 
The purpose of this study is to determine the effectiveness of implementing cost 
saving strategies from the civilian sector in the MHS pharmaceutical benefit program.  In 
order to do so, a brief background of the Military Health Care System and the population 
it serves will be provided in Chapter II.  Chapter III is a description of the civilian 
pharmacy cost trends that occurred over the past decade and a discussion on civilian 
utilization management practices.  Chapter IV will cover the military pharmacy cost 
trends and utilization management practices.  In addition, it will include a comparison of 
drug utilization patterns and drug expenditure patterns of military beneficiaries with that 
of civilian beneficiaries.  Chapter V concludes the thesis by discussing the effectiveness 
of various current utilization management strategies as applied to the MHS, and considers 
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II. THE MILITARY HEALTHCARE SYSTEM 
A. OVERVIEW  
 The approach used by the Department of Defense to provide medical services to 
the armed forces of the United States is unique and unparalleled. The military health care 
system is responsible for achieving two missions: first, to provide and maintain readiness 
and medical support to military operations, and second, to provide a comprehensive 
health benefit to its eligible beneficiaries (Evaluation of the Tricare Program, 2006).  
The wartime/operational readiness mission is a uniquely military mission and 
requires that medical personnel and equipment are ready to deploy in support of military 
operations to include: war, peacekeeping and humanitarian operations, and military 
training.  Additionally, the readiness mission requires that the military health system 
perform activities that will assure that all military personnel are medically ready and 
prepared to deploy in support of any of these types of military operations.   
The purpose of the benefits mission is to provide everyday comprehensive 
healthcare to the beneficiary population.  This mission is continual; it does not go away 
when active duty medical personnel and equipment are deployed. Both missions are 
accomplished through a provision of health coverage plans that first utilized the capacity 
that exists in Military Treatment Facilities, the direct care system, regardless of any 
current military operations, and then expands health coverage through purchased care 
from civilian providers, also known as the indirect care system.  This makes it possible 
for the DoD to accomplish both missions simultaneously.   
The MHS beneficiary population consists of active duty and retired members of 
the Army, Navy, Air Force, and Marine Corps, and their dependents, along with active 
members of the Coast Guard, the National Oceanographic and Atmospheric 
Administration and members of the Public Health Service and their dependents.   The 
healthcare benefits that they receive differ from the benefits received by those who work 
for civilian companies.  Military healthcare is an entitlement, thus an MHS beneficiary 
has a legal right to the benefits specified by United States law.  Eligibility is defined 
under article 32 of the Code of Federal Regulation.  At the end of fiscal year 2005, there 
were approximately 9.2 million people of all ages eligible for care through the Military 
4 
Health System (Figure 1).  Figure 1 separates the MHS beneficiaries into six categories 
and shows the corresponding population and the percent of the total MHS beneficiary 
population of each beneficiary category.      
Figure 1.   Number of Eligible Beneficiaries by Category 

























B. THE HISTORICAL FRAMEWORK 
 To evaluate and determine the effectiveness of the Tricare pharmacy benefit 
strategies, it is important to understand the current state and structure of MHS.  To do 
this, it is necessary to briefly review the system’s origins and historical policy decisions.  
The Department of Defense’s military health system began in 1775, when the Continental 
Congress established the medical service in support of a 20,000 man army (Evolution of 
the Continental Army Medical Department).  Congress slowly enacted changes to this 
legislation that eventually lead to permissive care for dependents, and subsequently for 
retirees and their dependents.   
 At first, all medical care was provided within the military treatment facilities that 
were owned and operated by the Department of Defense, also known as the direct care 
Source: After DEERS and MHS administrative Data, 
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system.  However, in 1956, the Dependents’ Medical Care Act was passed and authorized 
the Department of Defense to purchase care, from civilian health services, as a way to 
supplement the direct care capabilities.  This assured that military dependents had access 
to continuous health coverage and was the beginning of the purchased care system 
(Burrelli, 1991).  
 Having the authority to enhance the MHS with purchased care, the Department of 
Defense chose to access civilian health services on a cost-reimbursement basis.  This fee-
for-service program became known as the Civilian Health and Medical Program of the 
Uniformed Services (CHAMPUS) (Burrelli, 1991).  The CHAMPUS cost schedule for 
reimbursing civilian providers was similar to that of Medicare.  As with Medicare, the 
fees paid to reimburse civilian providers for their services began to increase substantially.     
  By the late 1970s, escalating costs had many questioning the sustainability of the 
military health system.  However, the MHS was not the only health system feeling the 
pressures of out-of-control health care costs.   Annual double digit increases in health 
care costs became the norm throughout the health care industry, in both public and 
private health care systems.  Congress responded to these increases by mandating DoD to 
implement cost containment practices similar to those occurring in the civilian health care 
industry.  They soon began to look for ways to structure the system using a managed care 
structure.  
1. The Beginning of Managed Care 
 To help transform CHAMPUS into a managed care system, three significant 
issues were identified: the need for better integration of direct and purchased care, 
establishment of an enrollment system, and the creation of a Military Health Care 
Account (H.R. Rep. No. 99-718, at 237-246 (1986)).  
 Throughout the 80s and into the early 90s, the Department of Defense initiated 
demonstration projects to help determine how to transition into managed care.  The 
process of developing a plan to transition the military health system into a managed care 
system was heavily scrutinized and governed by Congress and the Government 
Accounting Office.  In 1993, Congress directed the DoD to develop a Health 
Maintenance Organization (HMO) benefit option that was modeled on both private sector 
and other government health insurance options.  This HMO benefit was to then be 
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included in all future initiatives.  The beneficiary cost shares associated with this HMO 
option were to be no greater than those that would be incurred under the traditional 
CHAMPUS fee-for-service structure (National Defense Authorization Act, 1994).   In 
1995, the MHS’ HMO was born, now known as the Tricare program. 
2. TRICARE  
 Tricare brought together the health resources of the direct care and the indirect 
care systems.  In accordance with Congressional mandates, Tricare offered beneficiaries 
three primary options (Tricare: the basics, 2003): 
(1) Tricare Standard:  This option was similar to CHAMPUS and offered 
traditional indemnity fee-for-service benefit.  It allowed beneficiaries to use 
non-network providers.  It was open to all beneficiaries except active duty 
service members; no enrollment necessary.  This option was the least cost 
effective and had the most expensive cost shares for beneficiaries. 
(2) Tricare Extra:  This option was similar to a civilian preferred provider 
network or PPO.  Beneficiaries had the option of enjoying reduced cost 
sharing through the use of civilian providers that were part of the Tricare 
Prime network of contracted professionals or hospitals.  No enrollment was 
required to use the contracted network. 
(3) Tricare Prime:  A tightly managed HMO like benefit requiring that each 
beneficiary enroll in the program.  Each enrollee was assigned a primary care 
provider who coordinate and manage their care.   
These Tricare options were available to retirees and their dependents until they 
reached the age of 65 and became eligible for Medicare.  Once beneficiaries were eligible 
for Medicare, it replaced Tricare as the payer for medical services.  These over 65 
beneficiaries did remain eligible for care and service on a space-available basis through 
the direct care system.  The military began to draw down the active duty force in the late 
80s and many bases began to close.  These base closures combined with an emphasis on 
ensuring Tricare Prime enrollees had access to cost effective care through the direct care 
system meant that less space was available to see non-prime or Medicare eligible patients 
in the direct care system.  Medicare benefits were not comparable to those offered 
through Tricare and the out of pocket cost shares of Medicare were also higher.  It could 
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be argued that this policy resulted in an erosion of benefits for beneficiaries when they 
reached the age of 65.  Military retirees and their dependents over the age of 65 were the 
only federal government personnel prevented from using their employee-provided 
healthcare after reaching the age of 65  (Burrelli, 2000). 
 Since the implementation of Tricare, the cost of healthcare continued to grow in 
the MHS and, like the civilian sector, pharmaceuticals were seen as a large contributor to 
these escalating expenditures.  U.S. Congress inevitably identified the pharmacy benefit 
as an area for reform and, through Section 701 of the National Defense Authorization Act 
for Fiscal Year 2000, they directed the Secretary of Defense to establish an effective, 
efficient, and integrated pharmacy benefits program for the MHS beneficiaries. 
C. THE PHARMACY BENEFIT 
The Tricare pharmacy benefit is available to all beneficiaries regardless of the 
Tricare program option in which they participate.  It provides coverage for virtually all 
Food and Drug Administration approved prescription medications and attempts to make 
these medications conveniently accessible.  Beneficiaries have the option to fill their 
prescriptions using any of four points of service: Department of Defense outpatient 
pharmacies located in military treatment facilities; the Tricare Mail Order Pharmacy 
(TMOP); a network of retail pharmacies (TRRx) that have contracted with Tricare to 
provide services; and non-network retail pharmacies. 
Since the advent of Tricare, prescription drug costs and utilization of the 
pharmacy benefit have steadily increased. The Department of Defense 
Pharmacoeconomics Center estimates that the amount spent on prescription drugs more 
than tripled in size in 2005 from $1.6 billion in 2000 to over $5.4 billion (PEC estimate 
using PDTS Data).  The increase and pharmacy utilization was attributed to changes in 
the beneficiary demographics and the propensity of physicians to prescribe more drugs.  
This was due to advances in pharmaceuticals which contributed to the increase in drug 
choices for treating and managing illnesses.  In addition to increased utilization, 
differences in drug prices at dispensing locations and the type of drugs being prescribed 
were also major contributors to the increasing costs of the MHS pharmacy benefit. 
 In an effort to control these escalating costs, the Tricare pharmacy program 
implemented utilization management practices that have been adopted from civilian 
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managed care organizations such as tiered co-payments and restricted formularies.  The 
objective of these practices is to allow beneficiaries the freedom to make convenient 
choices while providing incentives to use the most cost efficient pharmacy options. 
TRICARE Pharmacy Points of Service  
a. Military Treatment Facility Pharmacies 
  There are 536 MTF pharmacies operated by 121 MTFs spread throughout 
the United States (Evaluation of the Tricare Program, 2006).  Beneficiaries can fill 
prescriptions with up to a 90-day supply of most medications at an MTF pharmacy free 
of charge.  MTF pharmacies will accept prescriptions written by any Tricare authorized 
provider, civilian or military, provided the medication is listed on the local MTF 
formulary.  Each MTF pharmacy is required to make available all drugs on the DoD 
Basic Core Formulary.  MTF pharmacies are the least costly place for beneficiaries to 
obtain prescription medications because they do not charge co-payments (Tricare 
Website, 2006).  In 2005, 47 percent of all MHS pharmacy workload was performed by 
MTF pharmacies accounting for 30 percent of total expenditures (DoD PEC data).  
b. TRICARE Mail Order Pharmacy 
The Tricare Mail Order Pharmacy (TMOP) is available for prescriptions 
that are taken on a regular basis.  The MHS has contracted with a pharmacy benefits 
management company, Express Scripts, to administer and operate the mail order 
pharmacy from a state of the art facility in Tempe, Arizona.  The TMOP is the largest 
mail order pharmacy in the United States.  Beneficiaries fill out a form and submit it 
along with their prescription to the TMOP.  The prescription drug is then mailed directly 
to beneficiary.  Like the MTF pharmacy, beneficiaries may request up to a 90-day supply 
of most medications.  There are co-payments associated with drugs dispensed through the 
TMOP.  Therefore, with the exception of active duty members, MHS beneficiaries are 
required to mail their co-payment along with the prescription.  Once submitted, 
prescriptions can be refilled by phone, mail, or online (Tricare Website, 2006).  In 2005, 
6 percent of all MHS pharmacy workload was performed through the TMOP, accounting 




c. TRICARE Retail Pharmacy Network  
There are over 54,000 civilian retail pharmacies that are part of the Tricare 
retail pharmacy network.  The MHS contracts with Express Scripts to administer and 
operate the TRRx.  Beneficiaries are only allowed to request up to a 30-day supply of 
medications through a TRRx.  There are co-payments associated with drugs dispensed 
through the TRRx (Tricare Website, 2006).  The TRRx represents 47 percent of the MHS 
pharmacy workload and 58 percent of the total expenditures.  Utilization of the TRRx is 
growing at a faster pace than the other two options even though it is clearly the most 
expensive option for the MHS (DoD PEC data).   
D.  DATA AND METHODOLOGY   
 The data and information used in preparing this thesis came from several sources.  
A comprehensive review was conducted of relevant policy manuals, literature, and other 
materials on the Military Health System, Tricare, the Tricare pharmacy program, and the 
civilian sector pharmacy.  As well, internal reports, communications, and briefing slides 
were provided by personnel at the Bureau of Medicine and Surgery and the Department 
of Defense Pharmacoeconomics Center.  Much of the information and many of the 
reports came from the Pharmacy Data Transaction Service, the Department of Defense’s 
fully integrated pharmacy information system operated by the DoD Pharmacoeconomics 
Center.      
This thesis will evaluate the Military Health System’s pharmacy benefit to 
identify cost drivers and evaluate strategies designed to reduce or contain these costs.  
The objective is to evaluate how effective current strategies are at reducing costs, and to 
determine if they could be used more effectively.  This research will also explore the 
purpose of existing strategies; are they designed to influence beneficiaries to make more 
cost effective choices when using their pharmacy benefit or simply mechanisms to shift a 
portion of the program’s costs directly to beneficiaries.  Research will include: 
conducting a detailed analysis of existing data, identifying utilization rates and trends, 



























III. CIVILIAN PHARMACY COST TRENDS AND UTILIZATION 
MANAGEMENT PRACTICES 
A. PRIVATE SECTOR PHARMACY COST TRENDS  
1.  Introduction 
Pharmacy utilization management practices typically applied by civilian health 
care organizations, such as tiered co-payments and restricted formularies, have been 
applied in the MHS.  The strategy for implementing these management practices is to 
provide beneficiaries with convenience and choice while still providing incentives and 
management oversight to efficiently control costs.  This chapter will examine current 
pharmaceutical industry cost trends and utilization management practices in the private 
sector.  The following chapter, chapter IV, will present the cost trends and utilization 
management practices occurring within the Military Health System, which will be 
compared with those occurring in the civilian private sector. 
2. Private Sector Health Care Cost Trends  
Health care costs in the private health sector have increased at an excessive rate 
and in 2005 accounted for 16 percent of Gross Domestic Product (National Health 
Expenditure, 2005).  As costs increase, private sector firms are finding it harder to 
provide the same level of health care benefits to their employees.  These excessive 
increases in health care cost have resulted in pressure to contain medical spending.  Some 
firms have reduced the health benefits offered to their employees or raised the portion of 
costs that the employees pay through cost sharing, or a combination of both, to contain 
healthcare costs.       
In 2004, the amount spent on health care in the United States was $1.9 trillion 
dollars, representing 16 percent of the Gross Domestic Product, which is up 7.9 percent 
from previous years (National Health Expenditure, 2005).  The Center for Medicare and 
Medicaid services forecasts that actual spending in the United States for health care in 
2015 will exceed $4.0 trillion dollars and will comprise 20 percent of Gross Domestic 
Product (National Health Expenditure, 2005).    
In 2005, an annual survey by the Kaiser Family Foundation and Health Research 
and Educational Trust, found that employer health insurance premiums rose by 9.2 
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percent in 2005.  This was consistent with annual double digit increases in health 
insurance premiums experienced during the previous five years.  This growth was much 
higher than the overall inflation of 3.5 percent.  It was also higher than employee wage 
growth of 2.7 percent experienced over the same period (Employer Health Benefits 
Survey, 2005).  Employee spending for health insurance coverage increased 126 percent 
between 2000 and 2004 (Health Care Expectations, 2005).  The survey also found that 
the percentage of employers offering health benefits to their employees fell from 69 
percent to 60 percent in 2005.  
As health care costs in the private sector increase, health insurance firms 
responsible for these costs are shifting more of the cost burden to their beneficiaries.  
Despite stagnate wage growth, the insurance premiums and co-payments of civilian 
beneficiaries continue to rise and the benefits offered through their health plans are 
declining.  Beneficiaries in the private sector are being forced to share in an increasingly 
greater portion of the burden of private sector health care costs.  As beneficiaries are 
forced to share a greater portion of the costs of health care, the law of supply and demand 
would indicate that these beneficiaries will likely change their behaviors and demand 
fewer health care services as their share of health care costs increases. 
3. Rising Expenditures for Prescription Drugs 
Prescription drug spending is the fastest growing component of the private health 
care sector.  From 1990 to 2005, prescription drug spending increased at annual double 
digit rates; increasing from $40.3 billion in 1990 to over $188.5 billion in 2004.  This was 
more than a 450% increase in spending (National Expenditure Accounts, 2005).  
During this period, private health insurance companies substantially increased the 
percent of drug expenses they paid.  In 1990, private insurance companies paid about 26 
percent of total drug costs.  In 2004, this had increased to 48 percent of total costs.  It is 
very likely that as drug costs increased more Americans opted to join health plans that 
offered prescription drug benefits.  As insurance companies paid a greater percent of the 
total cost of prescription drugs, the total share of the costs consumers paid for drugs 
decreased from 56 percent in 1990 to about 25 percent by 2004.  Drug prices had 
increased so significantly over this period that even with a substantial increase in the 
portion of drug costs paid by insurance companies the average consumer was forced to 
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pay substantially more out-of-pocket in 2004 for drugs than in 1990 (National 
Expenditure Accounts, 2005). 
4. Factors Increasing the Cost of Prescription Drugs 
 There are three main factors that appear to contribute to the escalating costs of 
private sector prescription drugs.  These factors are: increased utilization, the continual 
increase in wholesale prices, and changes in the types and number of drugs available for 
treating illnesses.   
a. Increased Utilization 
The aging and overall growth of the American population poses concerns 
for civilian health care organizations with regard to pharmacy cost and utilization.  As the 
life expectancies of Americans continue to increase, and the baby boomer generation 
grows older, the average age of the American population increases annually.  Americans 
over the age of 65 that are eligible for Medicare account for 12.6 percent of the total U.S. 
population (Census Bureau, 2006).  They require an average of 20 prescriptions a year.  
In comparison, the average person in his or her 20s requires an average of only 3 
prescriptions per year (Drug Benefit Trends, 2000).  
The increase in total population is another contributor to prescription drug 
utilization.  In the United States, the population has grown by 9 percent from 1994 to 
2005.  It surpassed 300 million in 2006, making the United States the third most 
populated country in the world (Census Bureau, 2006).  These trends will undoubtedly 
increase demand for prescription drugs. 
Overall, the number of prescription drugs purchased increased by 71 
percent between 1994 and 2005; from 2.1 billion prescriptions filled in 1994 to over 3.6 
billion filled in 2005.  The average number of retail prescriptions per capita increased 
from 7.9 in 1994 to 12.3 in 2005 (National Expenditure Accounts, n.d.).  Americans are 
using more prescription drugs to treat and manage medical conditions than in the past.   
b. Drug Price Increases 
The price of prescription drugs increases substantially every year.  Retail 
prices increased at an annual average rate of 8.3 percent from 1994 to 2005.    The 
average retail price in 1994 was $28.67 and had increased to $64.86 by 2005 (Industry 
Facts at a Glance, n.d.).  The main contributor to the increase in retail drug prescription 
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expenditures has been the increase in wholesale drug prices.  The average wholesale 
prices for all drugs increased 7.1 percent in 2004 and 6.6 percent in 2005 (Associated 
Press, 2005).  These increase are less than the increase experienced over the previous ten 
years, but are still indicative of the over all trend of wholesale drug prices outpacing 
general inflation by two or three times. In fact, for this period, these increases are more 
than twice the 2.5% average general rate of inflation experienced over the same time 
period (Consumer Price Index, n.d.).  Large annual increases in wholesale drug prices are 
major contributors to the increases in prescription drug costs.  Any increases in 
manufacturers' wholesale prices get passed through the system, regardless of the final 
purchaser.  
 c. New Drugs 
New drugs entering the market also contribute to the increase in drug 
spending.  Often new drugs entering the market have one of three purposes: to replace an 
older, less expensive medication that is about to loose its patent; to supplement existing 
drugs used in treatment; or to treat a condition that was not previously treated through 
drug therapy.  The new drugs replacing older drugs that are loosing their patents are often 
designed to do more than the drugs they replace, or in some way become more user 
friendly (e.g. the new drug is taken once a week vice once a day).  Drugs are often 
introduced that are not designed to replace another drug, but to supplement it.  Society 
has evolved to demand a quick answer to everything, a trend that also applies in 
medication treatment.  This attitude has resulted in more care focusing on treatment of 
symptoms of illness as apposed to cures to the illness.  Many new drugs are being 
introduced to provide relief from these symptoms with no regard to curing the actual 
illness.  Regardless of the purpose for which a drug enters the market, it usually results in 
an increase in spending.   
B. PRIVATE SECTOR UTILIZATION MANAGEMENT PRACTICES 
1. Responses to Increasing Prescription Costs 
As private sector prescription drug prices continue to rise, pharmacy utilization 
management has become one of the top priorities among private sector insurance 
organizations, particularly in today's health care environment where 4 of every 5 people 
who visit their physician leave with a prescription (NACDS, n.d.). These private sector 
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health plan managers have implemented a variety of strategies to attempt to contain the 
rising costs of prescription drugs.  They have implemented utilization management 
strategies and attempted to negotiate discounts or rebates.  
Many plans have responded to increasing prescription drug costs by excluding 
certain drugs from coverage, using quantity dispensing limits and increasing enrollee 
cost-sharing amounts. In 2005, about three-quarters (74%) of workers with employer-
sponsored coverage had a cost-sharing arrangement with 3 or 4 tiers.  This was two and a 
half times more than plans requiring tiered cost sharing in 2000 (Employer Health 
Benefits, 2005).  Co-payments for non-preferred drugs (those not included on a formulary 
or preferred drug list) doubled from an average of $17 in 2000 to $35 in 2005. Co-
payments for preferred drugs (those included on a formulary or preferred drug list, such 
as a brand name drug without a generic substitute) increased by 69%, from $13 in 2000 
to $22 in 2005 (Prescription Drug Trends, a chart-book, 2000). 
Figure 2.   Average Drug Co-payments, 2000 to 2005 





































Source: After Kaiser Family Foundation and Health Research and Educational Trust, Annual Survey of 
employer-Sponsored Health Benefits, 2000-2005 data  
 
2. Pharmacy Utilization Management Strategies 
Nearly all private health insurance companies employ some combination of 
pharmacy utilization management strategies and best business practices to control 
pharmacy costs, and most centrally administer these programs. The business practices 
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and strategies used to control drug program costs are designed to influence the behaviors 
and attitudes of stakeholders in the pharmacy benefits process. These stakeholders 
include the administrators, drug manufacturers, pharmacies/pharmacists, and consumers 
(Kreling, 2000).  Centralizing pharmacy administrative activities represents the first step 
in developing an effective pharmacy utilization management program. Many of the other 
utilization management strategies, such as information systems integration, manufacturer 
rebates, and formulary uniformity rely on this centralization to be conducted efficiently. 
a. Fully Integrated Pharmacy Information Systems 
The most important utilization management strategy is the design and 
implementation of a fully integrated pharmacy information system. The value of such an 
information system in successfully managing pharmacy benefit programs cannot be 
overemphasized. To be fully utilized, these systems must serve as more than just data 
repositories; they must be integrated decision support tools for prospective utilization 
management by pharmacists and administrators.  Most private sector health care 
organizations use these systems to collect, analyze, and report data for disease 
management, provider profiling, and to monitor trends.  They also use these systems to 
conduct prior authorization, online edits, and other prospective drug utilization review 
(PDUR) programs (Edlin, 2001).  A fully integrated pharmacy information system is the 
key to tracking, storing and accessing comprehensive prescription drug cost and use data.  
This information is central in managing the pharmacy benefit.   
b. Formulary Management 
Formularies are a predefined list of covered or reimbursable drugs 
(Kreling, 2000). Recent studies have shown that the use of formulary management 
strategies can significantly reduce prescription drug utilization and costs (Motheral et al, 
2000).  These strategies are used to influence the utilization behaviors of providers and 
patients, and normally involve combinations of exclusions, limitations, and prior 
authorizations, as well as a tiered cost sharing mechanism. 
Formularies are most often defined as open, closed (restricted) or 
preferred (partially restricted).  Open formularies, as the name implies, include all 
available drugs. A closed or restricted formulary includes only those drugs that are 
approved by the pharmacy benefit manager.  Closed formularies may include only one 
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drug per drug class, or allow multiple drugs within each class (Kreling, 2000).  Preferred 
or partially restricted formularies also include only those drugs listed by the pharmacy 
benefits manager, but allow exceptions through prior authorization procedures or at an 
increased out of pocket expense to the patient (Kreling, 2000; DoD, 1999). 
Decisions to exclude drugs from a closed or preferred formulary are 
normally made based on cost and medical necessity.  Cost based drug exclusions are 
made for numerous reasons.  The benefits manager may have negotiated volume 
purchase agreements, which require them to restrict other similar drugs, or list drugs as 
preferred on their formularies.  Similarly, formularies may restrict brand name drugs in 
lieu of bioequivalent generics (Motheral et al, 2000).  On a partially restricted formulary, 
cost sharing by the patient may be increased for brand name or non-preferred drugs.  
Drugs may also be excluded from formularies because they are deemed medically 
unnecessary.  These drugs include those used for cosmetic situations or quality of life 
conditions such as vitamins or appetite suppressants (DoD Pharmacy Benefit Report, 
1999).  Quality of life drugs, such as Rogaine and Viagra, may have limitations imposed 
on the amount prescribed during a certain period of time.  Limitations may also be placed 
on certain drugs based on their potential for abuse or misuse (DoD Pharmacy Benefit 
Report, 1999). 
When developing formulary management strategies, it is important to 
balance cost reduction and patient satisfaction, as more than 70% of healthcare 
consumers cite pharmacy benefits as their primary reason for purchasing a health plan 
(Fahey, 1996). While it is generally accepted that formulary management can result in 
decreased utilization and lower costs, these strategies can also have a negative impact.  
Pharmacoeconomics represents an evolving field in which prescription drug utilization 
can be compared with the costs and outcomes of other medical treatments to improve the 
allocative decision-making process of formulary management (Evans et al, 2000). Recent 
studies suggest that the increased use of new and existing drugs may result in lower total 
health care expenditures overall.  Conversely, the restricting or limiting of use of these 
same drugs may result in higher health care expenditures (Grabowski, 1998).  Balancing 
unnecessary utilization and the economic benefits of prescription drugs through 
formulary management strategies can be controversial and difficult to achieve. 
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c. Generic Substitution 
  Prescription drugs come in two basic forms, brand name and generic 
drugs.  Generic drugs are copies of brand drugs whose patents have expired.  A generic 
drug is required to maintain the same active ingredients as the brand drug.  The main 
difference between a brand name drug and a generic drug is price and the way that they 
look.  The generic drug is much cheaper and legally must not look exactly like the name 
brand that it competes against.   
  Requiring the substitution of generic drugs for brand name drugs is a 
common cost reduction strategy used in the civilian health care industry.  As generic 
drugs are considerably less expensive than their brand name counterparts, an incentive 
exists to influence consumers, providers, and pharmacists to utilize generic alternatives 
whenever possible.  This is achieved through cost-sharing mechanisms, higher dispensing 
fees and maximum allowable cost (MAC) programs.   
  Cost sharing mechanisms are designed to target the consumer and often 
require a higher co-payment or coinsurance for brand name drugs that have a generic 
equivalent (Kreling, 2000). To provide incentives for the pharmacist/pharmacy to 
dispense generic rather than the brand name drugs, substitution strategies normally 
involve higher dispensing fees for generic drugs.  As a further incentive, the third party 
payers may only agree to reimburse at a MAC for generic drugs, thereby making the 
pharmacist/pharmacy responsible for the difference in cost between the generic and brand 
name drug (Kreling, 2000). 
d. Cost Sharing 
Cost sharing is a management strategy designed to influence utilization by 
shifting a portion of the prescription cost responsibility to the consumer (Kreling, 2000). 
Through cost sharing strategies, the consumer becomes aware of the differing costs for 
brand name and generic drugs by shifting a portion of the cost to them.  This is designed 
to influence them to make more cost effective choices.  Historically, these strategies 
required patients to make a fixed price co-payment that differs between brand and generic 
drugs for every prescription they fill regardless of the actual drug cost.  The co-payment 
for the brand drug is higher than that associated with generic drug, thus providing an 
incentive for the patient to use the generic drug.  According to a study by Wyeth-Ayerst 
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(1999), nearly 80% of employer prescription drug plans require some form of co-
payment for filling prescriptions in retail pharmacies.  Most private insurance companies 
have broadened this policy by adopting a three-tiered co-payment system that 
differentiates between generic, brand name, and formulary drugs (Penna, 2000).  In a 
three-tier co-pay system, generic or preferred drugs require the least co-pay, which is 
commonly set at $10.00 in most programs (Figure 2).  The second tier is for brand name 
medications and carries a co-payment that is normally about twice that of the first tier 
(Penna, 2000). The third tier requires the highest co-payment, averaging $35 in most 
plans today (Figure 2), and is commonly reserved for newly approved medications and 
expensive non-formulary drugs (Penna, 2000). 
In addition to tiered co-payments, coinsurance is a mechanism also used in 
cost sharing.  Coinsurance strategies require patients to pay a percent, such as 25 percent, 
of the drug cost for each prescription being filled.  Similar to the tiered co-payment 
systems, this percentage may vary depending on whether the drug is generic, brand name, 
or non-formulary; this is less common in coinsurance cost sharing strategies (Kreling, 
2000). Coinsurance rates vary, but are usually set at between 20 and 30 percent of the 
drug cost (Kreling, 2000).  As prescription prices continue to increase, more of the 
economic burden is being shifted to the consumer.  This could potentially influence 
patients to forego expensive drug treatment or to utilize less effective drugs because they 
are less expensive.  Such behavior could potentially have a negative impact on health 
outcomes, as well as on future healthcare expenditures. 
e. Volume Purchase Price Negotiations 
  Many health plans have attempted to use their purchasing power to 
negotiate discounts or rebates with drug manufacturers.  The larger the health plan, the 
more power they have in negotiating lower discounts.  It is becoming more common for 
smaller health plans to combine their negotiating power by working with a pharmacy 
benefit manager.  A pharmacy benefit manager pools the smaller health plans together 
and thus increases their negotiating power.  This power is gained through the ability to 
control market share.  If the manufacturer wants its drug to remain on the health plan’s 
formulary and to be available to the consumer, they are required to provide a discount or 
rebate.  Negotiations for discounts and rebates work best when there are competing 
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manufacturers that produce similar drugs and as generic drugs are introduced into the 
market. 
These volume purchase price negotiations are a commonly used cost management 
strategy within the civilian health care sector.  Pharmacies that agree to the negotiated 
prices are included in the network of pharmacy providers.  Drug manufactures that agree 
to the negotiated prices have their drugs remain on the formulary, usually meaning that 
their competitor’s drugs are excluded.  According to Kreling (2000), these negotiated 
prices based on volume and a restricted network can be some of the lowest in the country. 
The actual pharmaceutical prices that are negotiated represent an ingredient cost plus a 
dispensing fee that varies depending on whether the drug is generic or brand name 
(Kreling, 2000). The ingredient cost for a brand name drug is normally calculated by 
deducting a certain percentage from the average wholesale price (AWP). In a survey 
conducted by Wyeth-Ayerst in 1998, this deduction averaged about 13%. For generic 
drugs, or those drugs for which the patent period has expired, the price may be calculated 
in the same manner, or by a maximum allowable cost (MAC) per unit dispensed (Kreling, 
2000). 
f. Additional Practices 
Consumers are using a variety of strategies to reduce prescription drug 
costs.  Many are asking their physicians to prescribe the cheapest available drug or 
specifically asking for generic drugs.  They are beginning to compare drug prices using 
the Internet and are more apt to compare prices than just a few years ago.  Some are 
choosing to use a cheaper over-the-counter drug in place of their prescribed drug.  They 
are also buying drugs in bulk and pill-splitting, using mail-order pharmacies, and using 
pharmaceutical company or state drug assistance programs (Herrick, 2004). 
Recently, there have been some health plans, and even some States, that have 
attempted to influence Congress to pass laws that would allow drugs to be purchased 
from distributors outside the United States.  Purchasing prescription products from 
distributors in other countries is called importation or reimportation if the drugs were 
originally manufactured in the US.   It is currently not lawful for individuals or 
commercial entities, such as pharmacies or wholesalers, to purchase prescription drugs 
from other countries.  However, the government does not always enforce these laws.  It is 
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estimated that prescription drug purchases from Canada through Internet sales and travel 
to Canada, totaled about $700 million in 2003.  It is believed that an additional $700 
million in imported drugs entered the country from the rest of the world, mostly through 
the mail and courier services (Report on Drug Importation, 2004).  The actual amount 
saved by importing is often disputed, but it is acknowledged that identical drugs cost less 
outside the United States.  There are also concerns about drug safety and marketplace 
competition. 
C. OUTLOOK FOR THE FUTURE 
Despite a greater focus on developing and implementing pharmacy utilization 
management practices, prescription drug spending in the United States is projected to 
continue increasing substantially over the next decade.  Prescription drug spending is 
projected to increase from $188.5 billion in 2004 to over $446.2 billion by 2015.  This is 
a projected increase of 138 percent.  The yearly increases are expected to average around 
8.4 percent annually, through 2015.  Drug spending as a percent of overall health 
spending is projected to increase from 10% in 2004 to 11% in 2015. Over the next 
decade, Health and Human Services projects that the largest contributing factor in drug 
expenditure increases will be due to increased utilization because of the aging of the 
American population (Borger et al, 2006). 
 Although the projected increase of 8.4 percent annually is well above the inflation 
rate, it is lower than what was experienced during the past decade.  Much of this slow 
down is attributable to using lower cost substitutes, such as generic drugs.  Brand name 
drugs are protected from competition from generic drugs until their patents expire.  Once 
a patent expires, generic drugs can be produced that compete with these brand name 
drugs.  Over the next four years, patents for 30 of the top 60 most prescribed brand name 
drugs will expire (Fuhrmans, 2006).  Currently, 53 percent of all prescriptions filled in 
the United States are filled with generic drugs; with 30 of the top 60 brand name drugs 
loosing their patents, the percent of generic drugs being used should increase, resulting in 



























IV. TRICARE PHARMACY COST TRENDS AND UTILIZATION 
MANAGEMENT PRACTICES 
A. TRICARE PHARMACY COST TRENDS 
1. Introduction  
Like in the private health sector, prescription drug expenditures in the military 
health system have experienced rapid growth over the past decade.  These trends are 
likely to continue as the beneficiary population continues to age and as drug research and 
development results in new or improved drugs to treat and manage larger quantities of 
medical conditions and illnesses.  Increased pharmacy utilization and the rising cost of 
prescription drugs within the Military Health System are further exacerbated by the 
dispensing location used by the beneficiaries to fill their prescriptions.  A considerable 
cost difference exists between the types of dispensing locations offered through the 
Tricare pharmacy benefit; retail pharmacies are by far the most expensive option for the 
military health system.  Current trends have increased the cost of providing the 
prescription drug benefit at a faster rate than any other single component of the military 
health system over the past five years.     
The Military Health System has adopted many pharmacy utilization management 
practices such as tiered co-pays and restricted formularies.  The strategy for 
implementing these management practices, is to provide beneficiaries with convenience 
and allow choice while still providing incentives and management oversight to efficiently 
control costs.  This chapter will present the cost trends and utilization management 
practices occurring within the Military Health System. 
2. Rising Expenditures for Prescription Drugs 
Like in the private sector, prescription drug spending is the fastest growing 
component of the Military Health System.  The Department of Defense’s 
Pharmacoeconomics Center estimates that the military health system spent approximately 
$1.6 billion on prescription drugs in fiscal year 2000 and that spending had increased to 
over $5.4 billion by fiscal year 2005.  This $3.8 billion increase in the cost of prescription 
drug benefit represents a 338 percent increase in costs (PEC estimate using PDTS Data).   
This is very similar to the growth experienced within the private sector.   Figure 3 
24 
demonstrates how the cost of providing the pharmacy benefit has more than tripled 
between 1995 and 2005.   
Figure 3.   DoD Drug Expenditures FY 1995 thru FY 2005 
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 The MHS, unlike the private sector, has not attempted to offset these increasing 
drug expenditures by shifting a larger portion of the expenditures to the beneficiary.   
When TRICARE began, the MHS implemented a two tiered co-payment schedule.  Since 
then, there has only been one change made to this pharmacy co-payment schedule.   
 In 2001, Congress mandated expansion of the pharmacy coverage to include the 
1.8 million military retirees and their dependents over the age of 65, increasing the 
beneficiary population eligible for the pharmacy benefit by nearly 25 percent.  This 
mandate created the TRICARE Senior Pharmacy Program.  Prior to this expansion, these 
retirees and dependents could only use the military prescription benefit at MTF 
pharmacies on a space available basis, where prescriptions were dispensed at no cost to 
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beneficiaries.  Under the Tricare Senior Pharmacy Program these over 65 beneficiaries 
could now fill their prescriptions at any of the four sources, MTF pharmacies, retail 
network pharmacies, the Tricare Mail Order Pharmacy, or non-network retail pharmacies.   
This sudden increase in eligibility was expected to correspond with an increase in 
utilization.  If these new beneficiaries chose to fill a majority of their prescriptions at 
retail pharmacies using brand names drugs, then Tricare pharmacy expenditures would be 
significantly higher than if they filled them with generic drugs at MTF pharmacies or 
through the TMOP, especially for high-price, widely prescribed drugs used to treat 
chronic illnesses. To incentivize these over 65 beneficiaries, and all beneficiaries for that 
matter, to fill a large portion of prescriptions using less costly generic and formulary 
drugs at the MTF pharmacies, Tricare replaced the existing co-payment schedule with a 
three-tiered co-payment schedule.  The new co-payment schedule not only applied a co-
payment of $3 for a generic drug and $9 for a brand drug dispensed at retail pharmacies 
and TMOP, as the old schedule did, but also required beneficiaries to pay a $22 co-pay 
for any drug not on the preferred formulary. 
3. Factors Increasing the Cost of Prescription Drugs 
The main factors that appear to contribute to the escalating expenditures of 
prescription drugs within the MHS are similar to those affecting the private sector.  These 
factors are: increased utilization and dispensing location choices, the drug acquisition 
prices and changes in the types and number of drugs available for treating illnesses. 
Though the factors are the same, there is a slight twist in how and to what extent each of 
these factors is affecting expenditures for prescription drugs within the Military Health 
System.     
a. Increased Utilization 
Since 1995, the demographic population of the MHS has increased and 
aged significantly. The population of eligible active duty beneficiaries and their family 
members has steadily declined.  This decline has been offset by a steady increase in the 
population of retirees and their family members, resulting in a beneficiary population that 
is older and 8.6 percent larger.  It is intuitive to understand that as a population ages it 
becomes sicker and uses more prescription drugs.  This increase and aging of the 
beneficiary population in fact increases utilization of prescription drugs.  The increase in 
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use due to age can be demonstrated by reviewing the increase in the average number of 
prescription drugs used per beneficiary per year.  From 2003 to 2005, the average number 
of prescription drugs per beneficiary increased by 19 percent (Evaluation of the Tricare 
Program, 2006).          
b. Increased Use of Retail Network Pharmacies 
  Expenditures for prescription drugs obtained from retail pharmacies, 
network or non-network, are typically much higher than those dispensed through MTF 
and the TMOP.  This is primarily due to volume purchase price negotiations and the 
interpretation of the Veterans Health Care Act of 1992.  Drugs dispensed at MTF 
pharmacies and the TMOP are purchased at prices negotiated directly with drug 
manufacturers by the Defense Supply Center in Philadelphia and the Department of 
Veterans Affairs.  These negotiated prices do not apply to retail pharmacies and, as such, 
the prices at retail pharmacies can be two and even three times as much. 
Figure 4 illustrates the significant variations in costs that exist across the 
three points of service and the effect that dispensing locations have on prescription drug 
expenditures within the Tricare pharmacy distribution network.  Figure 4 is based on 
acquisition costs of the top 50 brand name pharmaceuticals and it compares them across 
each of the dispensing locations.  The average cost of dispensing the top 50 most 
prescribed drugs is nearly 40 percent higher at a retail pharmacy than at a Military 
Treatment Facility pharmacy.  Despite the significant savings that can be realized by the 
beneficiary, there are no co-payments when filling prescriptions at MTF pharmacies, and 
Tricare beneficiaries fill prescription drugs at Military Treatment Facility pharmacy, the 














Figure 4.   Prescription Drug Cost Analysis by Dispensing Location 
Averages for 90-day supply of Brand Name Drugs
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 The general pattern over time, as illustrated in Figure 5, demonstrates that 
Tricare beneficiaries are filling more of their prescriptions at retail pharmacies.  The 
proportion of drugs dispensed at retail pharmacies dramatically increased while the 
proportion of prescriptions dispensed at MTFs actually declined.   The TMOP also saw 
an increase in use, but not nearly as dramatic as the retail pharmacies.  This trend has 
serious financial implications as the acquisition costs of prescriptions drugs dispensed at 











Figure 5.   Dispensing Locations Used by Tricare Beneficiaries 
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c. Drug Price Increases 
The Military Health System relies on the private sector drug 
manufacturing industry to procure prescriptions drugs.  As previously discussed, when 
analyzing cost drivers in the private sector health care industry, the price of prescription 
drugs has increased substantially every year since 1995.  These increases have been two 
or three times the rate of inflation.  Despite being able to negotiate volume price purchase 
discounts, these increases in manufacturers' prices get passed through the system, 
regardless of the final purchaser.  Increases in drug prices impact the retail pharmacy 
more than the other two dispensing locations, as federal prices negotiated through volume 
purchase price negotiations are not applied at retail pharmacies.    
d. New Drugs 
   The physicians that practice in the MHS are well educated and extremely 
professional.  Perhaps more than their counterparts in the civilian health care sector, they 
are encouraged to continually and aggressively seek continued medical education.  Drug 
representatives also visit military physicians and explain new drug treatments.  As new 
drugs enter the market, military physicians and beneficiaries are just as likely to be 
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exposed to the drug and its uses as are their civilian sector counterparts.  In this way, the 
introduction of new drugs impacts the MHS in much the same manner earlier presented 
for the private sector.   
B. PHARMACY UTILIZATION MANAGEMENT PRACTICES  
1. Response to Increasing Prescription Drug Costs 
As a result of increasing prescription drug costs, the U.S. Congress mandated that 
the Tricare pharmacy benefit be reformed and adopt best practices being used in the 
civilian sector.  Under title 10, U.S. Code, Section 1074g, Congress required the 
Secretary of Defense to establish an effective, efficient, and integrated pharmacy benefits 
program.  This is to be accomplish by implementing a uniform formulary, based on 
relative clinical effectiveness and cost effectiveness; establishing cost sharing 
requirements, including a tiered co-payment structure for drugs based on their 
designation as generic or brand and formulary or non-formulary; assure that drugs not on 
the formulary are available at a non-formulary co-payment; and implementing other 
civilian practices.  The Department of Defense has been developing an integrated 
pharmacy benefit and implementing civilian utilization management strategies since the 
beginning of TRICARE in 1995.  In 2004, they began to reform and redesign the 
pharmacy program into a single, integrated program.  This is being accomplished through 
standardized formulary management, promoting the use of generic drugs, encouraging 
beneficiaries to use cost effective dispensing locations to fill prescriptions and applying 
volume purchase price negotiations.  
 In spite of these efforts to manage more efficiently, Tricare pharmacy 
expenditures continue to rise.  Much of this growth can be attributed to the increase in 
utilization due to a growing and aging beneficiary population, the expansion of benefits 
and the introduction of new drugs into the market.        
a. Fully Integrated Pharmacy Information Systems 
  The Military Health System implemented a fully integrated pharmacy 
information system, known as the Pharmacy Data Transaction System (PDTS), between 
December 2000 and June 2001.   The PDTS is a centralized data repository that was 
created to improve patient care, reduce pharmacy related costs, capture drug utilization 
and expenditures, and produce pharmacy management reports (IPS/PDTS, 2006). 
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  PDTS is fully integrated across the dispensing locations available to 
Tricare beneficiaries; Military Treatment Facility pharmacies, TMOP, and the Tricare 
network of retail pharmacies.  PDTS is also integrated with the MHS electronic medical 
record.  By being fully integrated, PDTS can be used to gather data from all locations and 
store this data at a central repository that can be viewed by military physicians.  PDTS is 
also used to create a common patient medication profile for all beneficiaries.  
Establishing a common patient medication profile improves quality and enhances patient 
safety by reducing the likelihood of adverse drug to drug interactions or duplicate 
treatments.  Physicians and pharmacists can view the complete medication history of a 
patient before prescribing or dispensing a drug.  Most civilian organizations do not have 
an electronic medical record that is integrated with their pharmacy information system; 
thus civilian physicians cannot view the complete medication history as in the MHS.  
Since the system launched in 2000, approximately 171,000 potentially life-threatening 
drug interactions have been identified and prevented (Department of Defense, 2006).  
  PDTS is located at Brooks Air Force Base in San Antonio, TX and 
administered by the Department of Defense Pharmacoeconomics Center (PEC).  PDTS 
collects data for every prescription prescribed and filled at Military Treatment Facility 
pharmacies, TMOP and retail network pharmacies.  This data is then used to build reports 
and management tools that can track drug usage and cost trends.  PDTS is also used to 
analyze formulary management and provide information to assist in making utilization 
management decisions (IPS/PDTS, 2006).   Like the civilian sector fully integrated 
pharmacy systems, the value of the PDTS system as a tool in successfully managing the 
TRICARE Pharmacy benefit cannot be overemphasized nor fully quantified. 
b. Formulary Management  
The MHS is directed under title 10, U.S. Code 1074g, to establish an 
effective, efficient, integrated pharmacy benefits program that includes a Uniform 
Formulary for pharmaceutical agents.  The progress in becoming compliant with this 
direction was an evolving process until the Department of Defense published a Final Rule 
on April 1, 2004, to implement the Military Health System’s formulary management 
program.  The formulary management program covers all drugs dispensed through 
Military Treatment Facility pharmacies, the TMOP and Tricare retail network 
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pharmacies.  Formulary management is accomplished through the establishment of the 
Uniform Formulary, the Basic Core Formulary and the Extended Core Formulary (HA 
Policy: 04-032). 
 Uniform Formulary The uniform formulary process establishes which 
drugs will be covered under the TRICARE pharmacy program, or carried on the Uniform 
Formulary.  All drugs are classified as either formulary, meaning they are on the Uniform 
Formulary, or non-formulary, meaning they are not on the Uniform Formulary.  Under 
the Final Rule, the Department of Defense Pharmacy and Therapeutics Committee was 
established to consider the relative clinical effectiveness and cost effectiveness of all the 
drugs within a therapeutic class and then recommend which medications should be 
included or excluded from the Uniform Formulary.  Drugs are then classified into the 
categories of generic, formulary, or non-formulary according to their formulary status.  
This process also determines under which of the three cost-share tiers a drug is covered 
under and the appropriate co-payment to be charged.  Military Treatment Facility 
Pharmacies are not permitted to carry non-formulary drugs, and they are not required to 
carry all drugs on the Uniform Formulary (HA Policy: 04-032). 
  Basic Core Formulary To assure that there is uniformity among the drugs 
carried at Military Treatment Facility pharmacies, the Military Health System also 
established and uses a Basic Core Formulary (BCF).  The BCF is a subset of the Uniform 
Formulary and only drugs classified on the UF are included on the BCF.  The BCF is a 
formulary that contains a minimum set of drugs from each therapeutic class that are 
required to support the primary scope of practice found in the Military Health System.  
The DoD P&T Committee identifies a subset of drugs within each therapeutic class that 
provides the greatest value among all within the class and, based upon relative clinical 
and cost effectiveness, requires the drug to be on the BCF and allows other UF drugs 
from the same therapeutic class to be excluded.  Recognizing that not all Military 
Treatment Facilities provide full service, the formulary management policy makes 
exceptions for limited service Military Treatment Facility pharmacies and there is a 
process by which they can gain permission to exclude some BCF drugs.  However, they 
are required to maintain those BCF drugs that are appropriate to the needs of the patients 
they serve.  The BCF applies only to Military Treatment Facility pharmacies and does not 
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affect the TMOP or the Tricare retail network pharmacies.  The BCF is a minimum 
requirement and Military Treatment Facility pharmacies may get permission to carry one 
or more of the remaining drugs listed on the UF within a therapeutic class not on the BCF 
(HA Policy: 04-032).  
Extended Core Formulary The Extended Core Formulary (ECF), like the 
BCF, only applies to Military Treatment Facility pharmacies and does not impact the 
TRICARE Mail Order Pharmacy or Tricare retail network pharmacies.  The ECF 
includes drugs within therapeutic classes that are used to support specialized scopes of 
practice that are not included on the BCF but are included in the UF.  A Military 
Treatment Facility is not required to carry any drugs except those on the BCF, however, 
if a Military Treatment Facility has a specialized scope of practice and the drugs required 
to support this specialized scope are not on the BCF, the Military Treatment Facility must 
include these drugs in their ECF.  The ECF becomes a subset of drugs in therapeutic 
classes other than those covered by the BCF that a Military Treatment Facility with a 
specialized scope of practice must have.   If a Military Treatment Facility pharmacy 
includes a therapeutic class that is on the ECF, then all of the drugs that are on the ECF 
within that class must be carried by the facility’s pharmacy (HA Policy: 04-032).   
The MHS employs a closed formulary management strategy at Military 
Treatment Facilities, and a preferred or partially restricted formulary strategy at the 
TMOP and at Tricare retail network pharmacies.  In 2005, it is estimated that the Military 
Health System saved $500 million through improved formulary management (Tricare, 
2006).  Like civilian sector organizations, the Military Health System has been able to 
use formulary management to save costs and provide safe effective drug treatment to 
Tricare beneficiaries. 
c. Generic Substitution 
Requiring the substituting of generic drugs for brand name drugs is a 
common civilian cost reduction strategy.  The Military Health System has a mandatory 
generic substitution policy that has been in place for 10 years. The main reason for 
mandating the use of generic drugs is that they are safe and much less expensive than 
brand name drugs; a prescription filled with a generic drug will cost, on average, $40 less 
per prescription (PDTS data).  The table below lists the 10 most expensive brand name 
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drugs that have a generic equivalent available and compares the costs associated with 
each.    In many cases the difference in the cost is dramatic.  
Table 1.   Comparison of Brand Name Drug Cost with Generic Drug Costs 
Comparison of Brand Name Drug Costs to Generic Drug Costs 
 
Brand name Brand Average Wholesale 
Price (AWP) 
Generic name Generic Cost 
Generic 
Savings
PROZAC 20 MG $169.49  FLUOXETINE HCL 20MG  $5.40  $164.09 
PRILOSEC 20 MG   $143.45  OMEPRAZOLE 20 MG  $45.00   $98.45  
ZANTAC 150MG $94.68 RANITIDINE HCL 150MG $3.60 $91.08 
WELLBUTRIN XL 150 MG  $120.49  BUPROPION EXT REL  $34.80  $85.69  





IMDUR 60MG $79.48 ISOSORBIDE MONONITRATE 60 MG $5.10 $74.38 
BUSPAR 15 MG $76.50 BUSPIRONE HCL 15MG $8.10 $68.40 
HYTRIN 5MG $75.69 TERAZOSIN HCL 5MG $9.00 $66.69 
VALIUM 5MG $64.15 DIAZEPAM 5MG $1.35 $62.80 
ZOCOR 20MG $164.02 SIMVASTATIN 20MG $109.50 $54.52 
Source: From Department of Defense Pharmacoeconomics Center  
 
Under the generic drug policy, brand name drugs that have a generic 
equivalent can only be dispensed if the prescribing physician is able to justify medical 
necessity for using the brand name drug in place of the generic equivalent.  This can be 
justified if the generic doesn't work for the beneficiary, causes adverse side effects, or the 
beneficiary's doctor can assert that there is a medical necessity to prescribe the brand-
name drug.  If the medical necessity determination is approved, the beneficiary can get 
the brand-name drug for the $9 co-payment.  In 2005, less than 1 per cent of patients 
qualified for the medical necessity exclusion.   
The generic substitution policy is resulting in a greater use of generic 
drugs.  According to the Department of Defense Pharmacoeconomics Center, generic 
drugs accounted for 43 percent of prescription drugs dispensed in 2003, and increased 11 
percent to just over 54 percent in 2005 (PDTS data).   This is attributable to the 
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implementation of the three tiered co-payment structure that provides an incentive to use 
generic drugs, improved formulary management practices, and greater enforcement of the 
generic drug policy. 
d. Cost Sharing 
As briefly touched upon earlier, the Military Health System uses a cost 
share strategy that incorporates a three-tiered co-payment schedule; this is consistent with 
the private sector’s preference to use three-tiered schedules.  The three-tiered schedule 
used by the Military Health System is designed to differentiate prescription medications 
by generic, formulary or non-formulary drug category and somewhat differentiates 
between dispensing locations.  There is no co-payment if prescriptions are filled at MTF 
pharmacies and the co-payment schedule is the same when using the TMOP or the TRRx, 
however, there is a higher cost share associated with using a non-network retail pharmacy 
(see Table 2).  The schedule is the same for all Tricare beneficiaries except active duty 
service members, who receive medications free-of-charge at all locations, but can not 
obtain non-formulary drugs at any location unless medical necessity is established 
(Tricare webpage).  
Table 2.   Tricare Pharmacy Co-payment Schedule 
Tricare Pharmacy Co-payment Schedule  
Formulary  






Military Treatment Facility 
(MTF) pharmacy 
(up to a 90-day supply)  
$0  $0 Not Applicable 
Tricare Mail Order 
Pharmacy (TMOP) 
(up to a 90-day supply)  
$3 $9 $22 
Tricare Retail Pharmacy 
Network pharmacy (TRRx) 
(up to a 30-day supply)  
$3  $9 $22 
Non-network retail 
pharmacy  
(up to a 30-day supply)  
 
Note: Beneficiaries using 
non-network pharmacies may 
have to pay the total amount 
of their prescription first and 
then file a claim to receive 
partial reimbursement.  
For those who are not enrolled in 
Tricare Prime: $9 or 20 percent of 
total cost, whichever is greater, 
after deductible is met (E1-E4: $50/ 
person; $100/family; all others, 
including retirees, $150/person, 
$300/family)  
 
Tricare Prime: 50 percent cost 
share after point-of-service 
For those who are not enrolled 
in Tricare Prime: $22 or 20 
percent of total cost, whichever 
is greater, after deductible is met 
(E1-E4: $50/ person; 




Tricare Prime: 50 percent cost 
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deductibles ($300 per person/$600 
per family deductible)  
share after point-of-service 
deductibles ($300 per 
person/$600 per family 
deductible)  
Source: From Tricare Webpage (www.Tricare.mil) 
 
  The current co-payment schedule is designed to differentiate between 
categories of drug, (generic, brand name, formulary or non-formulary) and, to a lesser 
degree it also differentiates between where a prescription is filled; providing an incentive 
to use MTF pharmacies and a stick when using non-network retail pharmacies.  There are 
no co-payments associated with any drugs when using an MTF pharmacy.  There are less 
out-of-pocket costs associated with using generic drugs ($3 co-payment) compared to 
brand name drugs ($9 co-payment) or non-formulary drugs ($22 co-payment) at the 
TMOP or TRRx.  Under this co-pay schedule, using a non-network retail pharmacy is 
comparatively expensive; the greater of $9 or 20 percent of total cost for formulary drugs 
and the greater of $22 or 20 percent of total cost for non-formulary drugs.  This co-
payment structure is designed to influence beneficiaries to choose the less costly generic 
drugs before brand name drugs and to use formulary drugs instead of non-formulary 
drugs; this is consistent with how the civilian sector uses three-tiered co-payment 
schedules.   
It is interesting to note that this co-payment schedule does not provide any 
out of pocket incentive for beneficiaries to differentiate between the TMOP and the 
TRRx, even though the drug expenditures associated with the TRRx are considerably 
larger than the other two points of service.  The schedule provides an incentive for 
beneficiaries to differentiate between generic, formulary, and non-formulary drugs and 
encourage the use of generic.    It should be noted that after implementing the three-tiered 
system, the expenditures associated with the retail network pharmacy and TMOP 
expanded at significantly larger rates than those associated with the Military Treatment 
Facility pharmacies (see Figure 3) 
  The co-payment amounts in the MHS are much lower than those in the 
civilian sector and have not experienced the same high growth in cost sharing; the MHS 
is not shifting the cost to beneficiaries.  From 2000 to 2005, the MHS co-payments were 
relatively constant while the civilian sector co-payments increased substantially.  The 
36 
average co-payment for a brand name drug in the civilian sector rose from $13 in 2000 to 
$22 in 2005 (see the previous chapter) compared to the MHS’s constant co-payment of 
$9 for brand name drugs.  The co-payment for generic drugs increased from $7 in 2000 to 
$10 in 2005 in the private sector, while it remained constant at $3 in the MHS.   Though 
not implemented in the MHS until 2002, the co-payment associated with the third tier 
non-formulary drugs is $22 in the MHS, which is much less than the $35 dollars currently 
charged in the civilian sector.    
  In the private sector, cost shares and co-payments have consistently risen 
and civilian organizations continue to reduce benefits and shift more of the economic 
burden to their consumers.  The Military Health System has not followed this trend. Co-
payments and cost shares have been relatively constant and are much lower in the 
Military Health System than in the private sector.         
e. Volume Purchase Price Negotiations 
  Through volume purchase price negotiations, an organization can use 
buying power provided through economies of scale and market share as leverage when 
negotiating discounts and rebates with pharmacies and drug manufacturers. When 
procuring drugs, the Military Health System has several options available for obtaining 
lower prices.  The federal government has used volume purchase price negations and 
legislative power with great success to obtain discounts on prescription drugs.  The 
Veterans Health Care Act of 1992 established federal ceiling prices (FCPs) for 
government covered pharmaceuticals and requires a minimum of a 24 percent discount 
off non-federal average manufacturing prices.  These FCPs apply to drug manufacturers 
when providing prescription drugs to the Military Health System. 
  Another source of drug discounts is through Federal Supply Schedule 
(FSS) contracts.  When drug manufacturers enter into contracts with a department within 
the federal government, the Veterans Health Care Act of 1992 requires that these drug 
manufacturers list their drugs on the FSS to receive Medicaid reimbursement for their 
products (DoD Pharmacy Benefit Report, 1999; GAO, 2001).   Under the law, drug 
manufacturers must also sell brand name drugs listed on this schedule to the DoD at no 
more than 76% of the manufacturer's average nonfederal price.  The most widely used 
purchasing vehicle in the federal government is the federal supply schedule for 
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pharmaceuticals. Using the FSS, the Military Health System can purchase prescription 
drugs 50 to 58 percent below the average wholesale price (GAO, 2001). In addition to 
these options, the Military Health System can negotiate contracts directly with drug 
manufacturers to obtain prices lower than the FSS or FCP.   
  In the Military Health System, volume purchase price negotiations have 
been used to target the drug manufacturers rather than the retail pharmacies. The MHS 
has been able to procure the majority of their drugs supplied to pharmacies in MTFs and 
the TMOP programs through the Defense Supply Center in Philadelphia (DSCP) using a 
prime vendor system for delivery (DoD Pharmacy Benefit Report, 1999).  This has 
allowed the Department of Defense to secure significant volume discounts from the drug 
manufacturers.  Prescription drugs dispensed through MTFs and the TMOP are therefore 
significantly less than those of civilian organizations. 
In addition to FPC and FSS, the Military Health System uses two other 
types of purchasing vehicles to secure "best federal prices" for prescription drugs (GAO, 
2001).  The MHS may be able to further reduce drug costs by negotiating blanket 
purchase agreements (BPA) and committed use (requirements) contracts with 
manufacturers.  BPAs offer variable discounts and require specific volumes of the 
negotiated drugs be purchased and listed in a preferred status on the basic core formulary 
(GAO, 2001).  To enter committed use or requirements contracts the Military Health 
System works with the Veterans Administration to conduct drug reviews to identify 
brand name drugs that are therapeutic alternatives within the same class.  As a result of 
these reviews, one drug is selected for adoption based on price, and the respective class is 
closed to other drugs on the formulary.  Similarly, following bioequivalence tests, the 
DoD secures committed use contracts for generic drugs by conducting competitions for 
an exclusive contract with one manufacturer. Providers are then required to prescribe, and 
MTF pharmacies are required to stock and dispense these drugs. Purchase costs for 
committed use contract drugs are an average of 33% below FSS prices (GAO, 2001). 
While these venues for obtaining lower prices are available for 
pharmaceuticals procured for MTF pharmacies and the TMOP, they have not been 
applied to the cost of prescription drugs dispensed through Tricare retail network 
pharmacies.  Drug manufacturers have been able to successfully argue that the Veterans 
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Health Care Act of 1992 does not apply to the Tricare retail network as these pharmacies 
are not owned or operated by the federal government.  Manufacturers do not believe that 
the government has a legal right to obtain federal pricing in its retail pharmacy network.  
The Department of Defense is taking steps to challenge this, but legal interpretation 
continues to be a point of dispute between the manufacturers and the Department of 
Defense.  Both sides are preparing to file lawsuits in federal court (Basu, 2005) 
C. ADDITIONAL COMPARISONS  
1. Evaluation of Pharmacy Utilization: Tricare Beneficiaries Compared 
to Civilian Beneficiaries 
 It is important to understand how pharmacy use among Tricare beneficiaries 
compares with the pharmacy use among civilian beneficiaries with similar drug benefits.   
An analysis was performed by the Health Program Analysis and Evaluation Directorate, 
Tricare Management Activity that compared drug utilization rates of Tricare beneficiaries 
to those of civilian benchmarks with similar prescription drug coverage.  Table 2 
represents the findings of this analysis.  The data compared the two groups between 2003 
and 2005.  Prescription drug utilization is hard to quantify, as prescription drugs come in 
different forms, quantities and dosages.  In this analysis, prescription counts from all 
sources were normalized by computing the total days supply for each and dividing by the 
average days supply for retail prescriptions (28.5 days).  The civilian data was adjusted 
for each year to reflect the age and sex distribution of the military health system’s 
beneficiary population. 
Table 3.   Prescription Utilization Rates 
PRESCRIPTION UTILIZATION RATES 
Average Annual Prescriptions per Enrollee 
 2003 2004 2005 
Tricare Prime vs. Civilian HMO Benchmark 
Tricare Prime 10.5 10.14 10.71 
HMO 6.87 7.79 9.05 
Non-Prime vs. Civilian PPO Benchmark 
Non-Prime 7.49 8.43 8.94 
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PPO 11.00 10.73 11.01 
All Tricare Beneficiaries vs. Civilian Benchmark   
Tricare  8.77 9.27 9.83 
Benchmark 8.94 9.26 10.03 
All Tricare Beneficiaries vs. Prime vs. Non-Prime 
Tricare  8.77 9.27 9.83 
Prime 10.5 10.14 10.71 
Non-Prime 7.49 8.43 8.94 
Source: Health Program Analysis and Evaluation Directorate, Tricare Management Activity using MHS 
administrative data and the Medstat Group, Inc., MarketScan Commercial Claims and Encounters database, 
12/26/2005 
 
According to this data, Tricare beneficiaries use slightly fewer prescription drugs 
per beneficiary than the organizations they were benchmarked against (see Figure 6).  
This would appear to indicate the Military Health System is experiencing similar 
utilization trends as the civilian health care industry.  However, comparing TRICARE 
prime beneficiaries to an HMO benchmark, coupled with a comparison of the non-prime 
beneficiaries with the utilization rates of a civilian PPO benchmark, provided conflicting 
results.   
 Tricare Prime Enrollees used more prescription drugs than did the benchmark 
HMO enrollees (see Figure 7).  The total prescription utilization rate for Tricare Prime 
enrollees increased by 7 percent between FY 2003 and FY 2005 compared to a 32 
percent increase in utilization by the HMO benchmark.  This comparison indicates that in 
2005 Tricare prime enrollees had an annual average prescription utilization rate that was 
about 18 percent higher than the benchmark HMO rate.   
The complete reverse appears to be occurring when comparing the Non-Prime 
enrollees to a PPO benchmark.  The total prescription utilization rate for non-enrolled 
beneficiaries rose by 19 percent between FY2003 and FY 2005 while the PPO growth 
rate was essentially zero.  Despite the growth in utilization, the non-enrolled average 
annual prescription utilization rate per beneficiary was still 19 percent lower than the 
benchmark PPO rate. 
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The Tricare Pharmacy Benefit provides the same coverage for all Tricare 
beneficiaries, regardless of enrollment in Prime, Standard, or Extra. The pharmacy 
utilization management tools adopted by Tricare were not intended to segregate 
utilization patterns among the three health plan options; yet the data shows the Prime 
enrollees use more prescriptions than non-prime beneficiaries on an average annual per 
beneficiary basis. 
Tricare prime enrollees use 20 percent more prescription drugs than non-prime 
enrollees on an annual average basis.  The data also suggests that Tricare Prime enrollees 
are twice as likely to utilize MTF pharmacies to fill their prescriptions as are non-prime 
enrollees.  This may suggest that Moral Hazard is prevalent within the Tricare Prime 
enrollee population or it could indicate of adverse selection. 
Moral hazard is the tendency for people to use more of a product or service if they 
do not have to pay the full cost.  As the cost incurred by the person decreases, they have a 
tendency to use more; if the price incurred increases then the person will use less.  
According to the theory of moral hazard, beneficiaries will demand less products or 
services as co-payments increase and they will demand more as co-payments decrease.   
 Adverse selection occurs when someone that is sicker or uses more of a product 
or service chooses a plan that will allow them to access more of the product or service at 
a lower cost.  An individual that does not demand as much may not be as sensitive to the 
price because they are healthier and do not use the product or service as often. 
 There is a trend for TRICARE beneficiaries to fill more of their prescriptions at 
TRRx.  The proportion of drugs dispensed at retail pharmacies has dramatically increased 
while the proportion of prescriptions dispensed at MTFs has declined.  If this trend 
persists, then the prime beneficiaries using the MTFs will eventually begin using the 
TRRx.  These individuals use a larger portion of drugs and the TRRx is the most 
expensive venue.  If this higher drug use among prime beneficiaries is due to adverse 
selection, then these individuals are sicker, which is why they use more drugs.  If this 
higher drug use is because of moral hazard, then this migration to the TRRx with its co-
payment structure would lead one to believe that once Tricare prime enrollees begin 
using the TRRx their drug use will mirror that of the non-prime enrollee. 
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2. How Annual per Beneficiary Prescription Drug Expenditures 
Compare with Use by the Civilian Population 
The MHS prescription drug expenditures by beneficiary status are presented in 
table 4.  This data on MHS drug expenditure rates by beneficiary categories will be 
compared to civilian prescription drug expenditure rates.  Each beneficiary category will 
be compared with the U.S. civilian population broken down into groups based on 
similarity of age with the beneficiary category.  As an example, active duty military 
expenditures rates will be compared to the expenditure rates of the civilian population 
between 18 and 44 because the active duty military population is between the ages of 18 
and 44.  The most current civilian data available was from 2003, so the comparison will 
involve expenditure rates in 2003.  
Table 4.   Average Annual Prescription Drug Expenditures by beneficiary 
Category 
Average Annual Prescription Drug Expenditures by Beneficiary Category 
Beneficiary Category 2003 2004 2005 
Active Duty Military (age18 to 44) $158 $202 $210 
Active Duty Family Members (age 0 to 44) $245 $270 $311 
Retirees and Family Members < 65 (age 44 to 65) $554 $644 $723 
Retirees and Family Member > 65 (age 65 and older) $1133 $1422 $1627 
Overall  $430 $572 $515 
Source: MHS administrative data, 12/26/2005 
The civilian data for prescription drug expenditure rates by age group was taken 
from the Medical Expenditure Panel Survey (MEPS) website 
(http://www.meps.ahrq.gov/mepsweb/).  MEPS is a set of large-scale surveys of families 
and individuals, their medical providers, and employers across the United States. MEPS 
is recognized in the healthcare industry as one of the most complete data sources on the 
cost and use of health care and health insurance coverage. MEPS collects data on the 
specific health services used, the frequency of use, the cost of these services, and how 
they are paid for, as well as data on the cost, scope, and breadth of health insurance held 
by and available to the U.S. population.  Table 5 compares the average annual per 
beneficiary prescription expenditures with those of the general population of the United 
States broken down by similar age groups. 
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Table 5.   Comparison of MHS and Civilian Average Annual Prescription Drug 
Expenditures in 2003 
Comparison of MHS and Civilian Average Annual Prescription Drug 
Expenditures in 2003 
Beneficiary Comparison Military Health 
System Civilian Population 
Active Duty Military compared to civilian 
population age18 to 44 
$158 $342 
Active Duty Family Members compared 
to civilian population age 0 to 44 
$245 $263 
Retirees and Family Members < 65 
compared to civilian population age 44 to 
65 
$554 $995 
Retirees and Family Member > 65 
compared to civilian population age 65 
and older 
$1133 $1625 
Overall MHS population compared to 
total US population 
$430 $611 
Source: MHS administrative data, 12/26/2005 and MEPS data retrieved November 2006 
from http://www.meps.ahrq.gov/mepsweb/ 
This comparison between the annual average MHS expenditures per beneficiary 
category and civilian populations of similar ages indicates that the civilian population has 
higher average per beneficiary prescription drug expenditure rates.  The lower per 
beneficiary prescription expenditure rates for the MHS is consistent with the findings of 
the previous section where it was shown that the MHS beneficiaries fill fewer 
prescriptions per beneficiary than their civilian counterparts.  Because MHS beneficiaries 
fill fewer prescriptions per beneficiary than their civilian counterparts, it is reasonable to 
expect the expenditures per MHS beneficiary to be lower. 
There are two potential explanations for why per beneficiary utilization rates and 
per beneficiary expenditure rates are less in the MHS.  The MHS population may be 
healthier and MHS physicians may focus more on preventive medicines, such as 
mandatory flu shots, than their civilian counterparts thus the illnesses and severity of 
illness are lower.  This would require lower costing drugs and fewer of them to treat these 
less severe illnesses.  The second and more plausible explanation, based on the research 
in this thesis, is that the MHS has adopted pharmacy utilization management practices 
and applied volume purchase price negotiations more efficiently than the civilian sector.  
 
43 
3. Proposed Changes to the Pharmacy Co-payment Schedule 
 The current co-payment schedule was designed to differentiate between 
categories of drugs, generic, brand name, formulary or non-formulary, but does not 
effectively differentiate between where a prescription is filled.  Just as a co-payment 
schedule can differentiate between types of drugs by varying the co-payment required for 
each drug category, the schedule can differentiate between dispensing locations by 
varying the co-payment amount by where it is dispensed as well.  The MHS is unable to 
apply federal pricing to the TRRx and therefore it is much more expensive for the MHS 
to allow beneficiaries to use the TRRx in comparison to the TMOP or MTF pharmacies.   
The current co-payment schedule does not differentiate between TMOP and 
TRRx.  Also, because of military force reduction efforts there are fewer MTF pharmacies 
available.  There is a migration by beneficiaries from use of MTF pharmacies to the more 
expensive TRRx.  The main reason is that the cost to the beneficiary is less than the 
convenience and benefit of use the TRRx and there is no substantial difference in out of 
pocket costs.  A simple co-payment schedule change could provide incentives for 
beneficiaries to use the less costly TMOP or drive the extra miles to the MTF pharmacy.   
  In the field of economics, elasticity of demand is a measure of the sensitivity of 
amount demanded to changes in quantity or price. Price elasticity of demand measures 
the percentage change in quantity demanded resulting from a one-percent change in 
price.  If the quantity demanded only slightly responds to price it is said to be price 
inelastic, if quantity responds substantially it is said to be elastic.  The closer an elasticity 
measurement is to 0, the less elastic it is (Hosek, 2002). 
 A study conducted for DoD by the RAND Corporation determined that there is a 
wide range in the estimates of elasticity of demand for health care. The study found that 
the elasticity of demand tended to center on -0.17. This means that a one percent increase 
in the price of health care will lead to a 0.17 percent decrease in the quantity of health 
care purchased.  According to this study, the price elasticity of pharmaceuticals is similar 
to that of health care.  The study also showed that the price elasticity of demand is 
inelastic at lower levels of cost sharing.  There was evidence to suggest that there is a 
very high cross price elasticity of about .33 among drug substitutes.  Cross price elasticity 
is the measurement of how sensitive a product is to substitutions.  This indicates that a 
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tiered co-payment schedule can be an effective tool to influence behavior of beneficiaries 
(Hosek, 2002).  Differentiating co-payments offered at each location can influence a 
beneficiary to use the less costly location.   
The pharmacy co-payment schedule will change for all beneficiaries in 2007.  
These changes include: eliminating co-payments for generic drugs at the TMOP and 
increasing co-payments of generic drugs to $5 and formulary or name brand drugs to $15 
at the TRRx.  No changes will be made to the MTF co-payments. Table 6 shows the new 
co-payment schedule. 
Table 6.   FY 2007 Tricare Pharmacy Co-payment Schedule 
FY 2007 Tricare Pharmacy Co-payment Schedule  
 Generic drugs Brand-name drugs Non-formulary drugs 
Current co-pays       
Military Facility $0 $0 not available 
Mail order $0 $9 $22 
Retail $5 $15 $22 
Source: From Tricare Webpage (www.Tricare.mil) 
 This new benefits structure is timely and support the trends exhibited within the 
MHS.  Increasing co-payments from $3 to $5 for generic drugs at the TRRx while 
simultaneously dropping the co-payment for generic drugs at the TMOP will theoretically 
provide incentives for beneficiaries to use the TMOP or MTF to fill generic prescriptions.  
Likewise increasing the co-payment of formulary drugs from $9 to $15 dollars at TRRx 
should provide incentives for beneficiaries to choose generic drugs at the TRRx or to fill 
them at the TMOP for $9.  This new co-payment schedule should help to reduce 




A. IMPLEMENTATION OF UTILIZATION MANAGEMENT STRATEGIES 
BY THE MHS HAVE BEEN EFFECTIVE RELATIVE TO THE CIVILIAN 
INDUSTRY 
 Prescription drug spending is the fastest growing component of both the MHS and 
the private health care sector: both have experienced annual double digit growth in 
expenditures.  The cost drivers affecting each of them appear to be the same; increased 
utilization, out of control drug prices, and an increasing the number of new drugs to treat 
illnesses. 
As MHS pharmacy expenditures escalated, Congress responded by making policy 
changes that increase access to and coverage of the benefit while simultaneously 
mandating that the MHS adopt civilian sector utilization management strategies.  A 
comparison of the utilization management strategies being used by the civilian sector and 
those used by the MHS reveals that the MHS has adopted and implemented civilian 
sector utilization management strategies. 
 The implementation of PDTS has improved patient care and been instrumental in 
reducing pharmacy related costs, capturing drug utilization and expenditures, and 
producing pharmacy management reports.  This system provides seamless access to 
pharmacy utilization and cost data across all pharmacy points of service.  PDTS provides 
the information needed to make pharmacy utilization management decisions.   
 The MHS has structured many of its strategies to encourage beneficiaries to use 
less costly prescriptions.  The MHS has implemented an effective formulary management 
process by establishing the Uniform Formulary, the Basic Core Formulary and the 
Extended Core Formulary that identifies and categorizes drugs into three tiers.  The 
process used to determine which medications should be included or excluded from the 
formulary considers the relative clinical effectiveness and cost effectiveness of all the 
drugs within a therapeutic class.  This assures that drugs are categorized not only by cost 
but by best value.  The co-payment cost schedule is designed to differentiate between the 
three formulary tiers.  Higher co-payments are associated with drugs that have less value 
and lower co-payments are associated with higher value drugs.   
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The formulary process and cost sharing structure both promote the use of generic 
drugs.  This is a key factor in helping to control total prescription drug costs.  The MHS 
has gone further and has established a generic substitution policy.  The goal of all of 
these strategies is to ensure that there is a balance between quality of care and effective 
cost-containment strategies.   
The Department of Defense has used volume purchase price negotiation strategies 
to secure significant volume discounts from the drug manufacturers.  In fact, prescription 
drugs dispensed through MTF pharmacies and the TMOP are significantly less expensive 
than those of civilian organizations.  The MHS has been able to procure the majority of 
the drugs supplied to their pharmacies in MTFs and the TMOP through the DSCP using a 
prime vendor system for delivery.  This has allowed the Department of Defense to secure 
significant volume discounts from the drug manufacturers.  Prescription drugs dispensed 
through MTFs and the TMOP are significantly less than those of civilian organizations. 
The MHS has implement civilian sector utilization management strategies 
designed to slow increases in pharmacy expenditures.  Despite not shifting a greater 
portion of the cost to beneficiaries, the MHS has experienced results that are as good as 
or better than those experienced by the civilian sector.   If matching the results achieved 
in the civilian sector is the benchmark for success, then these strategies have been 
successful.      
  However, the Tricare Pharmacy program is projected to continue to increase at a 
faster rate than other components of the MHS.  Consequently, this continual increase in 
the pharmacy budget in proportion to the overall MHS budget demonstrates that the 
implementation of these civilian utilization management practices, though successful 
when compared to civilian benchmarks, have not sufficiently contained Tricare pharmacy 
expenditures. 
B. INCREASING THE CO-PAYMENT RATES OF THE CURRENT CO-
PAYMENT SCHEDULE WILL NOT DECREASE UTILIZATION  
Moral hazard, in the context of the Tricare pharmacy benefit and health care in 
general, is the tendency of people to unnecessarily demand or use more of a product or 
service because they do not have to pay the full cost.  The current Tricare pharmacy 
benefit requires a beneficiary to pay a very modest co-payment when compared to the 
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civilian sector.  These co-payments are in no way representative of the true cost of the 
benefit and some may argue that in relative terms the difference between the co-payment, 
$3 for generic and $9 for formulary, are so small compared to the actual cost that they do 
not provide incentives for beneficiaries to differentiate between them.  In relative terms, 
health care is virtually free to MHS beneficiaries when compared to the cost shares 
charged in the civilian sector ($10 for generic and $22 for formulary).  
In theory, the introduction of higher cost shares would raise the cost of the Tricare 
benefit for beneficiaries, which should lead to less demand or at least a more relevant 
awareness of the actual costs.  This should in turn provide an incentive for beneficiaries 
to make an educated decision when accessing care through the MHS and thereby increase 
the MHS’s ability to influence their behaviors through co-payments.  If this theory holds 
true, then civilian organizations with higher co-payments should have lower per 
beneficiary utilization rates and higher generic drug utilization than the MHS, while the 
utilization of generic drugs compared to formulary within the MHS should hold constant.   
In actuality, the Tricare beneficiaries have lower rates of per beneficiary 
utilization and expenditures when compared to the civilian population.  The utilization of 
generic drugs by Tricare beneficiaries has increased every year since the introduction of 
the three tiered co-payment schedule; today over 53 percent of all prescriptions filled in 
the MHS are generic.   This is similar to the generic utilization rates in the civilian health 
care industry.  This would seem to indicate that the current co-payments schedule does 
differentiate between drug tiers and provides as much incentive and behavior 
modification as the much higher rates charged in the civilian sector.  Proportionally 
raising each of the current co-payments in the schedule might not provide Tricare 
beneficiaries more incentive to change behaviors; it could just be a cost shifting 
mechanism.   
C. NEW CO-PAYMENT SCHEDULE INFLUENCES BENEFICIARIES TO 
DIFFERENCIATE BETWEEN WHERE PRESCRIPTIONS ARE FILLED 
 Utilization management practices alone have not contained the increasing Tricare 
expenditures.  Some of the driving forces behind the ever escalating Tricare pharmacy 
expenditures appear to be mainly due to continual benefit expansion and increased 
utilization of the benefit.  The current benefits structure is a much better option than any 
civilian plan as it is less expensive and provides better coverage.  In response to 
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escalating costs, the civilian sector is continually shifting a greater portion of the cost 
burden to their beneficiaries through higher co-payments and larger insurance premiums, 
or simply reducing the benefits they offer.  History shows that Congress’s response to 
escalating Tricare expenditures has been to implement civilian strategies to increase 
efficiency and cost effectiveness but simultaneously they increase benefits and reduce out 
of pocket expenses for beneficiaries.  As pressure to contain expenditures continues to 
mount, Congress may be swayed to change its past behavior and follow the civilian 
sector by shifting a portion of the cost burden to beneficiaries.  DoD officials have made 
efforts to encourage cost shifting.   
Defense Department officials included proposals to raise Tricare enrollment fees 
and deductibles in the FY 2007 budget request.  In this budget request, they also propose 
changing the pharmacy co-payment schedule.  Currently beneficiaries pay 12 percent of 
their total health care costs; this is well below the 25 to 30 percent that most civilians pay.  
DoD officials would like to have beneficiaries pay about 25 percent of the cost.  
According to the CBO, the assumption being used to estimate cost savings maintains that 
for every 10 percent increase in out-of-pocket costs, the number of beneficiaries using 
Tricare will fall by one percent.  This equates to a price elasticity of -0.10. This means 
that a one percent increase in the price of health care will lead to a 0.10 percent decrease 
in the quantity of health care purchased.  This is more conservative than the price 
elasticity estimate of the RAND study of -0.17.   If the CBO estimate of -0.10 is accurate, 
600,000 beneficiaries will drop out of Tricare by 2015 if the out of pocket expenses are 
increased to 25 percent.  DoD officials contend that the Tricare fee structure is only one-
third as costly to beneficiaries as similar civilian plans would be (Philpot, 2005).  It is 
obvious how reducing beneficiary coverage by 600,000 would decrease costs as well how 
shifting 25 percent of the total cost to beneficiaries would reduce the cost paid by the 
MHS by 13 percent (beneficiaries currently pay about 12 percent, 25 minus 12 is 13). 
  Maintaining the position of the past, Congress did not raise Tricare fees or 
deductibles.  However, they did allow the MHS to “reshape” the co-payment schedule of 
the Tricare pharmacy program.  The new co-payment schedule reshapes the incentives.  
This reshaping should discourage beneficiaries from purchasing maintenance drugs at the 
more expensive TRRx.  The $3 co-payment for generic drugs will rise to $5 in the retail 
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network but would be free by mail.  The current $9 co-pay for brand drugs would rise to 
$15 in the retail network and $10 by mail.  The new co-payment schedule appears to 
provide incentives for beneficiaries to make cost effective choices when choosing a point 
of service to fill prescriptions.  Based on the research in this thesis, incentivising 
beneficiaries to avoid the TRRx is an effective cost strategy.  Time will show if the co-
payments are large enough to actually influence the desired beneficiary behavior.       
D. APPLYING FEDERAL PRICING AT RETAIL NETWORK 
PHARMACIES WILL REDUCE EXPENDITURES 
The price that MHS pays for prescription drugs varies across the three points of 
service, in part because of the differences in statutory rebates and discounts that are 
applied at each point of service.  Currently, the most expensive point of service, TRRx, is 
also the most used by beneficiaries.  The reason that the TRRx is the most expensive is 
that DoD is unable to apply federal pricing at the TRRx, while it is able to do so at the 
MTF and TMOP.  
DoD would like to apply federal pricing at the TRRx and has made attempts to do 
so.  Drug manufactures are opposed to this and argue that there is no legal basis under the 
Veterans Health Care Act of 1992 for DoD to apply these discounts at the TRRx.   DoD 
would save an enormous amount of money if federal pricing was applied at the TRRx; 
conversely, every dollar saved by DoD would be a dollar lost by drug manufacturers.  
This issue is currently being debated by the U.S. Court of Appeals for the Federal Circuit.  
 Ultimately DoD must use all of these tools in a multifaceted approach to contain 
the escalating expenditures of the pharmacy program.  Incentivising beneficiaries to 
choose high value drugs dispensed through the least expensive point of service would 
dramatically impact the current expenditures.  If the DoD is unable to secure federal 
pricing at the TRRx they must ensure that beneficiaries have the appropriate incentives to 
migrate to the TMOP.  If not, dramatic cost shifting may be the only way to lower 
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